The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents
Abstract
Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough to estimate the long‐term risk. We conducted a retrospective cohort study of hepatitis C virus (HCV) patients who achieved SVR with DAAs from 129 Veterans Health Administration hospitals between January 1, 2015, and December 31, 2015, with follow‐up through September 30, 2018. We calculated the overall and quarterly HCC incidence rates. We examined the effect of demographic, clinical, and behavioral factors and the decline or increase of FIB‐4 and aspartate aminotransferase to platelet ratio index (APRI) on HCC risk. Among the 18,076 patients with SVR, 544 incident cases of HCC were diagnosed during the mean 2.9 years of follow‐up. The cumulative 1, 2, and 3‐year risks of HCC were 1.1%, 1.9% and 2.8%, respectively. Cirrhosis was strongly associated with HCC risk (adjusted hazard ratio = 4.13, 95% confidence interval = 3.34‐5.11). The quarterly incidence rate of HCC remained stable between 1.00 and 1.23/100 person‐years (PY) and 1.5 to 2.3/100 PY in patients with cirrhosis. The risk of HCC was the highest in patients who had persistently high FIB‐4/APRI and both with and without cirrhosis. HCC risk fell in patients with cirrhosis who experienced a decrease of FIB‐4/APRI scores yet remained higher than the accepted threshold for HCC surveillance. HCC risk was also higher in patients with alcohol use, older age, and infection with HCV genotype 3. Most patients treated at an early stage of liver fibrosis had a stable low risk. Conclusion : Patients successfully treated with DAAs and at risk of HCC did not regress after 3.6 years of follow‐up. HCC risk remained above the accepted thresholds for surveillance in patients with cirrhosis. These data have important implications for HCC surveillance in cured HCV patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,077
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Kanwal, F., Kramer, J., Asch, S. M., Chayanupatkul, M., Cao, Y., & El-Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.012 · Cited by 931
Self-citationOral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Landmark Analysis at the 25-Year Landmark Point
Dafni, U. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.957951 · Cited by 569
El‐Serag, H. B., Kanwal, F., Richardson, P., & Kramer, J. (2016) · Hepatology · doi:10.1002/hep.28535 · Cited by 411
Self-citationChou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00005 · Cited by 370
Calvaruso, V., Cabibbo, G., Cacciola, I., Petta, S., Madonia, S., Bellia, A., Tinè, F., Distefano, M., Licata, A., Giannitrapani, L., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.008 · Cited by 361
Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C
Maylin, S., Martinot–Peignoux, M., Moucari, R., Boyer, N., Ripault, M., Cazals–Hatem, D., Giuily, N., Castelnau, C., Cardoso, A. C., Asselah, T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.044 · Cited by 321
Davila, J. A., Henderson, L., Kramer, J. R., Kanwal, F., Richardson, P. A., Duan, Z., & El-Serag, H. B. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00006 · Cited by 299
Self-citation
Cited by
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Epidemiology of Hepatocellular Carcinoma
McGlynn, K. A., Petrick, J. L., & El‐Serag, H. B. (2021) · Hepatology · doi:10.1002/hep.31288 · Cited by 2,147
Self-citationEASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Self-citationThompson, M. A., Horberg, M. A., Agwu, A. L., Colasanti, J. A., Jain, M. K., Short, W. R., Singh, T., & Aberg, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1391 · Cited by 256
Cholankeril, G., Kramer, J. R., Chu, J., Yu, X., Balakrishnan, M., Li, L., El-Serag, H. B., & Kanwal, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.035 · Cited by 119
Self-citationTsai, P.-C., Kuo, H.-T., Hung, C.-H., Tseng, K.-C., Lai, H.-C., Peng, C.-Y., Wang, J.-H., Chen, J.-J., Lee, P.-L., Chien, R.-N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.019 · Cited by 82
Xiao, M.-Y., Pei, W.-J., Li, S., Li, F.-F., Xie, P., Luo, H.-T., Hyun Yoo, H., & Piao, X.-L. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107539 · Cited by 26
Metadata
- Authors
- Kanwal, F., Kramer, J. R., Asch, S. M., Cao, Y., Li, L., & El‐Serag, H. B.
- Venue
- Hepatology
- Published
- 2019-08-19
- Volume
- 71
- Issue
- 1
- Pages
- 44-55
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2950514720
- Cited by
- 277
- References
- 26
- FWCI
- 21.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.